DE60024604D1 - Xanthinderivate und analoge als zellsignalisierung inhibitoren - Google Patents
Xanthinderivate und analoge als zellsignalisierung inhibitorenInfo
- Publication number
- DE60024604D1 DE60024604D1 DE60024604T DE60024604T DE60024604D1 DE 60024604 D1 DE60024604 D1 DE 60024604D1 DE 60024604 T DE60024604 T DE 60024604T DE 60024604 T DE60024604 T DE 60024604T DE 60024604 D1 DE60024604 D1 DE 60024604D1
- Authority
- DE
- Germany
- Prior art keywords
- independently selected
- analogue
- membered ring
- ring structure
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 230000005754 cellular signaling Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 102000013462 Interleukin-12 Human genes 0.000 abstract 2
- 108010065805 Interleukin-12 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 210000000447 Th1 cell Anatomy 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004983 dialkoxyalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229940117681 interleukin-12 Drugs 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US288556 | 1999-04-09 | ||
| US09/288,556 US6774130B2 (en) | 1998-01-16 | 1999-04-09 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
| PCT/US2000/009139 WO2000061583A1 (en) | 1995-06-07 | 2000-04-07 | Xanthine derivatives and analogs as cell signaling inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60024604D1 true DE60024604D1 (de) | 2006-01-12 |
| DE60024604T2 DE60024604T2 (de) | 2006-08-24 |
Family
ID=23107627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60024604T Expired - Lifetime DE60024604T2 (de) | 1999-04-09 | 2000-04-07 | Xanthinderivate und analoge als zellsignalisierung inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1171442B1 (de) |
| JP (1) | JP2002541258A (de) |
| AT (1) | ATE312102T1 (de) |
| AU (1) | AU4205000A (de) |
| CA (1) | CA2369981A1 (de) |
| DE (1) | DE60024604T2 (de) |
| ES (1) | ES2254163T3 (de) |
| MX (1) | MXPA01010143A (de) |
| WO (1) | WO2000061583A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
| EP1781657B1 (de) | 2004-02-14 | 2013-03-27 | GlaxoSmithKline Intellectual Property Development Limited | Medikamente mit wirkung am hm74a-rezeptor |
| JP2005320309A (ja) * | 2004-05-02 | 2005-11-17 | Hokkaido Technology Licence Office Co Ltd | 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬 |
| US7393827B2 (en) | 2004-12-30 | 2008-07-01 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring β-cell mass and function |
| WO2007017261A1 (en) | 2005-08-10 | 2007-02-15 | Smithkline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| US8871764B2 (en) | 2005-08-29 | 2014-10-28 | University Of Virginia Patent Foundation | Lisofylline analogs and methods for use |
| JP5259408B2 (ja) | 2005-08-29 | 2013-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | リソフィリン類縁体とその使用方法 |
| AU2007286630A1 (en) * | 2006-08-23 | 2008-02-28 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Derivatives of uric and thiouric acid for oxidative stress-related diseases |
| EP1939197A1 (de) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-Ethinylxanthinderivate als selektive Antagonisten des A2A-Rezeptors |
| RU2459826C1 (ru) * | 2011-05-31 | 2012-08-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Циклогексиламмониевая соль [3-метил-1-н-пропил-7-(1-оксотиетанил-3)ксантинил-8-тио]уксусной кислоты, проявляющая антитромботическую активность |
| RU2459825C1 (ru) * | 2011-05-31 | 2012-08-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Соли [3-метил-1-н-пропил-7-(1,1-диоксотиетанил-3)ксантинил-8-тио]уксусной кислоты, проявляющие проагрегантную активность |
| TWI582095B (zh) * | 2011-11-11 | 2017-05-11 | 基利阿波羅有限責任公司 | Ａｃｃ抑制劑及彼等之用途 |
| ES2636835T7 (es) * | 2013-03-15 | 2018-11-20 | Hydra Biosciences, Inc. | Xantinas sustituidas y procedimientos de uso de las mismas |
| UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| CA3004798C (en) | 2015-11-25 | 2023-10-31 | Gilead Apollo, Llc | Ester acc inhibitors and uses thereof |
| EA201890910A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА |
| CA3004796C (en) | 2015-11-25 | 2023-11-14 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
| EP4364795A3 (de) | 2016-03-02 | 2024-08-14 | Gilead Apollo, LLC | Feste formen eines thienopyrimidindion-acc-hemmers und verfahren zur herstellung davon |
| WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
| WO2018054846A1 (de) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N3-cyclisch substituierte thienouracile und ihre verwendung |
| EP4122464B1 (de) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutische kombinationen zur behandlung von lebererkrankungen |
| CN109912598B (zh) * | 2019-03-27 | 2022-09-13 | 四川大学华西医院 | 防治炎症反应的核苷类衍生物及其应用 |
| RU2740926C1 (ru) * | 2020-09-02 | 2021-01-21 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные тиетансодержащих 1-бутил-3-метилксантинов, проявляющие антиоксидантную активность |
| CN119569744B (zh) * | 2024-11-19 | 2026-01-02 | 武汉大学人民医院（湖北省人民医院） | 吡喃吡啶酮生物碱类化合物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109161A0 (en) * | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) * | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| WO1994024133A1 (en) * | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| WO1995020589A1 (en) * | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| JPH09511496A (ja) * | 1994-02-18 | 1997-11-18 | セル・セラピューティックス・インコーポレーテッド | 細胞内メッセンジャー |
| US5801182A (en) * | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
-
2000
- 2000-04-07 DE DE60024604T patent/DE60024604T2/de not_active Expired - Lifetime
- 2000-04-07 WO PCT/US2000/009139 patent/WO2000061583A1/en not_active Ceased
- 2000-04-07 JP JP2000610854A patent/JP2002541258A/ja not_active Withdrawn
- 2000-04-07 ES ES00921774T patent/ES2254163T3/es not_active Expired - Lifetime
- 2000-04-07 AT AT00921774T patent/ATE312102T1/de not_active IP Right Cessation
- 2000-04-07 CA CA002369981A patent/CA2369981A1/en not_active Abandoned
- 2000-04-07 EP EP00921774A patent/EP1171442B1/de not_active Expired - Lifetime
- 2000-04-07 MX MXPA01010143A patent/MXPA01010143A/es active IP Right Grant
- 2000-04-07 AU AU42050/00A patent/AU4205000A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1171442A1 (de) | 2002-01-16 |
| MXPA01010143A (es) | 2003-07-14 |
| JP2002541258A (ja) | 2002-12-03 |
| DE60024604T2 (de) | 2006-08-24 |
| WO2000061583A1 (en) | 2000-10-19 |
| CA2369981A1 (en) | 2000-10-19 |
| ATE312102T1 (de) | 2005-12-15 |
| EP1171442B1 (de) | 2005-12-07 |
| AU4205000A (en) | 2000-11-14 |
| ES2254163T3 (es) | 2006-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60024604D1 (de) | Xanthinderivate und analoge als zellsignalisierung inhibitoren | |
| NO20055316L (no) | Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike | |
| NO20072116L (no) | Farmasoytiske forbindelser | |
| MXPA05006420A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal. | |
| CA2269815A1 (en) | Thienopyrimidines having pde v-inhibiting action | |
| DK0894084T3 (da) | Kanelsyrederivater og deres anvendelse som integrinantagonister | |
| DK1158973T3 (da) | Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser | |
| BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
| BG103984A (en) | Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | |
| MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
| PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
| AP2002002530A0 (en) | 2,4 diaminopyrimidine compounds useful as immunosuppressants. | |
| EP1396493A4 (de) | Heterocyclische verbindungen | |
| YU52403A (sh) | Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže | |
| CA2239705A1 (en) | Quinazoline-4-one ampa antagonists | |
| HUP0401598A2 (hu) | Heterogyűrűs vegyületek a vizeletvezető rendszer rendellenességeinek kezelésében való használatra, és ezeket tartalmazó gyógyszerkészítmények | |
| ES8801245A1 (es) | Un procedimiento para preparar derivados de piperidina | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| GEP20084284B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| ATE389655T1 (de) | Pyrimidinderivate | |
| MY143578A (en) | Piperazinediones as oxytocin receptor antagonists | |
| NO20022123L (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
| WO2002068421A3 (en) | Tricyclic compounds and their analogs as inhibitors of cytokine signaling | |
| EP0309425A3 (de) | Heterozyklische Derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS LLP, LONDON, GB |